J4

• 基础研究 • 上一篇    下一篇

胰高血糖素样肽-1类似物对实验性糖尿病大鼠的治疗作用

赵海军1,徐 琪2,张桂英1,刘 娅1,于 婷1,李鸿雁1,杨丽娜1,王洪莹1,谢丽波1   

  1. 1.吉林大学公共卫生学院营养与食品卫生教研室,吉林 长春 130021;2.杭州中肽生化有限公司,浙江 杭州 310018
  • 收稿日期:2006-05-29 修回日期:1900-01-01 出版日期:2007-05-28 发布日期:2007-05-28
  • 通讯作者: 刘 娅

Therapeutic effects of GLP-1 analog on rats with experimental diabetes mellitus

ZHAO Hai-jun1,XU Qi2,ZHANG Gui-ying1,LIU Ya1,YU Ting1,LI Hong-yan1,YANG Li-na1,WANG Hong-ying1,XIE Li-bo1   

  1. 1.Deptartment of Nutrition and Food Hygiene,School of Public Health,Jinlin University,Changchun 130021,China;2.Chinese Peptide Company,Hangzhou 310018, China
  • Received:2006-05-29 Revised:1900-01-01 Online:2007-05-28 Published:2007-05-28
  • Contact: LIU Ya

摘要: 目的:探讨胰高血糖素样肽-1(GLP-1)类似物对实验性糖尿病的治疗作用。方法:84只Wistar大鼠随机分为正常对照组、高脂饲料组、GLP-1类似物低剂量组、GLP-1类似物中剂量组、GLP-1类似物高剂量组、糖尿病模型组和阳性对照组。采用高脂饲料饲养和注射40 mg•kg-1 STZ方法建立实验性糖尿病动物模型。GLP-1类似物低、中、高剂量(1、10和100 μg•kg-1)治疗7及14 d后,采用酶化学方法检测空腹血糖(FPG);治疗14 d后,采用酶化学方法检测血清总胆固醇(TC)、血清甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL);采用放射免疫方法检测血清胰岛素和C肽。结果:GLP-1类似物高剂量组(100 μg•kg-1)大鼠较糖尿病模型组进食量明显降低(P< 0.01),中剂量组(10 μg•kg-1)、高剂量组(100 μg•kg-1)大鼠较糖尿病模型组饮水量均明显减少(P<0.01),各治疗组大鼠体重与糖尿病模型组比较差异均无显著性(P>0.05);GLP-1类似物高剂量组(100 μg•kg-1)、中剂量组(10 μg•kg-1)大鼠空腹血糖(FPG)较糖尿病模型组均明显降低(P<0.01);GLP-1类似物高剂量组(100 μg•kg-1)大鼠血清TG较糖尿病模型组显著性降低(P<0.01);GLP-1类似物中剂量组(10 μg•kg-1)、GLP-1类似物高剂量组(100 μg•kg-1)LDL较糖尿病模型组均明显降低(P<0.01);GLP-1类似物中剂量组(10 μg•kg-1)、高剂量组(100 μg•kg-1)血清胰岛素和C肽水平较糖尿病模型组均显著升高(P<0.05)。结论:GLP-1类似物可以通过多种途径在治疗实验性糖尿病中发挥作用。

关键词: 糖尿病, 实验性, 胰岛素, C肽

Abstract: To investigate the therapeutic effects of glucagon-like peptide-1 (GLP-1) analog on rats with experimental diabetes mellitus.Methods Eighty-four Wistar rats were divided randomly into normal control group,high fat forage group,low-dose GLP-1 analog group,middle-dose GLP-1 analog group,high-dose GLP-1 analog group,diabetes mellitus model group and positive control group.Diabetes mellitus animal models were induced with high fat forage and injection of 40 mg•kg-1 STZ.After 7 and 14 d of GLP-1 analog therapy,the level of fasting plasma glucose(FPG) was detected with enzyme-chemical method.After 14 d of GLP-1 analog therapy,the levels of serum total cholesterols (TC),triglyceride (TG),low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were detected with enzyme-chemical method. The levels of serum insulin and C-peptide were measured with immunoradiometric assay method .Results After 14 d of GLP-1 analog injection,food intake in high-dose GLP-1 analog(100 μg•kg-1)group was less than that in DM group(P<0.01); Water intake in middle-dose GLP-1 analog(10 μg•kg-1) group and high dose (100 μg•kg-1)group were less than that in DM group(P<0.01). There were no statistical differences of body weight between all therapeutic groups and DM group(P<0.05).The levels of FPG in middle-dose GLP-1 analog(10 μg•kg-1 ) group and high dose (100 μg•kg-1)group were lower than that in DM group(P<0.01).The level of TG in high-dose GLP-1 analog(100 μg•kg-1)group was lower than that in DM group(P<0.01).The levels of LDL in middle-dose GLP-1 analog(10 μg•kg-1) group and high dose (100 μg•kg-1)group were lo wer than that in DM group(P<0.01).The levels of serum insulin and C-peptide in middl e-dose GLP-1 analog(10 μg•kg-1) group and high dose (100 μg•kg-1)group were higher than that in DM group(P<0.05). Conclusion GLP-1 analog can paly an important role in treatment of experimental diabetes mellitus through multiple ways.

Key words: diabetes mellitus, experimental, insulin, C-peptide

中图分类号: 

  • R587.1